Transformational Change to Prevent and Manage PPH

Amplifying access to life-saving medicines

AMPLI-PPHI will generate evidence on the feasibility, acceptability, and cost-effectiveness of newly recommended postpartum haemorrhage (PPH) medicines across varying health settings in the Democratic Republic of the Congo, Guinea, India, and Kenya, create an enabling environment for the treatments to go to scale, and prepare the market for sustained availability of quality-assured medications. AMPLI-PPHI aims to dramatically reduce maternal mortality and morbidity from PPH.
Advancing PPH Prevention and Treatment

Postpartum haemorrhage (PPH) is the leading cause of maternal mortality worldwide. The risk of PPH and PPH-related morbidity and mortality disproportionately affects women in low- and middle-income countries, especially those who lack access to quality care due to poverty, geography, and/or cultural barriers. The World Health Organization (WHO) recommends oxytocin as the first-line medicine for preventing and treating PPH, and requires cold chain for transport and storage to maintain required potency. Many resource-limited settings fail to meet this requirement, resulting in uncertain quality of oxytocin at point of use.

WHO has recently recommended new or newer medicines and delivery approaches critical to reducing PPH-related mortality and morbidity in these settings. These include heat-stable carbetocin (HSC) for the prevention of PPH, tranexamic acid (TXA) for the treatment of PPH, and advanced distribution of misoprostol to prevent PPH during community-based births. Ensuring these medicines are quality assured and registered in countries, integrated into national clinical guidelines and health systems, consistently available where women deliver, and trusted by providers for use in real-world settings will help to end the needless deaths of women from PPH.

The Unitaid-funded Accelerating Measurable Progress and Leveraging Investments for Postpartum Haemorrhage Impact (AMPLI-PPHI—pronounced “amplify”) project (August 2022–July 2026) aims to dramatically reduce maternal mortality and morbidity from PPH. Jhpiego is leading AMPLI-PPHI in partnership with PATH and the International Federation of Gynaecology and Obstetrics (FIGO). Working hand in hand with governments from the Democratic Republic of the Congo, Guinea, India, and Kenya, AMPLI-PPHI will support countries to ensure that the right PPH medications are available at the right time, in the right place, for the right indication, and for the right patient across health systems, ultimately reducing maternal morbidity and mortality.

Key AMPLI-PPHI Focus Areas

AMPLI-PPHI is working with countries to bring long-term support and action to prevent and treat PPH with a focus on three key areas—generate evidence and project learning, create an enabling environment, and prepare the market.

Generate Evidence and Project Learning

AMPLI-PPHI will generate evidence on the feasibility, acceptability, and cost-effectiveness of newly recommended medicines across varying health settings. Implementation research, routine monitoring, and process learning data will be brought together to generate evidence to advocate for adoption and implementation of policies aligned to WHO guidance around these priority PPH medicines and delivery models, and to inform future implementation guidelines issued by WHO.

Project countries: Democratic Republic of the Congo, Guinea, Kenya, and India

Learning exchange countries: Madagascar, Congo-Brazzaville, Cameroon, Burkina Faso, Benin, Côte d’Ivoire, Mali, Bangladesh, Nepal, India (five additional states), Sri Lanka, Tanzania, Uganda, and South Africa
Create an Enabling Environment

As countries introduce these PPH medications and delivery approaches at all levels of the health system, AMPLI-PPHI will simultaneously support ministries of health to create enabling environments across the health system to effectively go to scale.

- **Advocacy:** Advocacy efforts, targeting national program managers and key stakeholders, focus on the key elements of implementation that are necessary for long-term success and may not already be in place. These include national policies that support consistent availability of quality-assured PPH medicines at all appropriate levels of the health system, funding availability to support national scale-up, improved pharmacovigilance, dissemination of national guidelines to frontline providers, and improved awareness of PPH care at the community level.

- **Capacity strengthening:** Following successful advocacy efforts, updating of national policies, clinical guidelines, and resources to integrate the three PPH medicines and approaches is a key step to set the stage for capacity strengthening. AMPLI-PPHI will apply a “low-dose, high-frequency” training approach, whereby providers receive training onsite, in both knowledge and skills, to incorporate the three medicines into clinical practice. Learning will be simulation- and team-based with ongoing peer-led practice sessions to aid in retention of clinical knowledge and decision-making. This will ensure the new medicines are integrated into clinical care algorithms along with other PPH management medicines and interventions.

- **Stakeholder engagement:** AMPLI-PPHI is coordinating and collaborating with key stakeholders at both global and country levels. From community to national levels, key stakeholders are contributing to efforts to build awareness and technical capacity on priority PPH medicines and to secure political and financial support around PPH, positioning countries for long-term success. At the global level, AMPLI-PPHI is coordinating with donors and partners through key advisory bodies to support broad dissemination of project learning and influence global conditions for scale-up. Engagement of civil society organizations and community leaders in project efforts is helping to increase opportunities for all pregnant women to receive quality PPH medicines at point of care. Community actors are also co-designing and implementing effective local strategies to generate awareness among communities about the extent of the PPH problem and increasing demand for quality intrapartum care, lending to ownership and scalability.

- **Country learning exchange:** While AMPLI-PPHI is working directly in four target countries, project resources, including evidence, tools, and products, will be shared across regions to catapult learning across countries. Defined as “exchange hubs,” each target country is linked with multiple “exchange” countries in their region to share learning so that these countries have the knowledge and tools to move forward with introduction and adoption of PPH medicines post-project.

- **Health systems strengthening:** AMPLI-PPHI is supporting ministries of health to strengthen health systems to ensure quality-assured products are available to prevent and manage PPH.
  - Support in-country value-based procurement practices to support purchasing decisions based on quality and total value of the drugs,
rather than solely based on the prices of the drugs, by developing a guidance document and convening workshops with government and nongovernment procurement agencies to co-refine the guidance document.

- Strengthen in-country supply chain mechanisms to ensure that the quality drugs are available at the lowest possible levels of health care systems by assessing existing supply chain mechanisms and identifying potential areas for optimization.

- Ensure correct use of the drugs by assessing the existing pharmacovigilance systems and including the key reporting factors for adverse events/reactions related to the three drugs into the training for health care workers participating in the demonstration studies.

### Prepare the Market

As countries demonstrate the use of HSC and advanced distribution of misoprostol for PPH prevention and TXA for PPH treatment, demand for these medicines is expected to increase. However, current market conditions for HSC, misoprostol, and TXA can pose challenges to sustained availability of quality-assured products of these medications, whether due to the lack of registered products or high prices of quality-assured products. To ensure long-term supply security and affordability of quality-assured products beyond the life of the project, AMPLI-PPHI will estimate market size and demand of the three PPH drugs to articulate the future prospect of these markets, conduct pricing assessments to improve transparency of market information, and perform analyses to identify cost drivers throughout the value chain. Using this market information, the project will develop business cases to secure manufacturers’ interest in supplying quality-assured products for the long term.

### Partnerships Matter

AMPLI-PPHI stands on decades-long efforts, led by countries, to improve maternal health outcomes and manage bleeding after birth. Jhpiego, together with PATH and FIGO, is proud to work hand in hand with national governments and ministries of health to “amplify” efforts that will improve access to safe and effective medicines to prevent and manage bleeding after birth.

This brief was made possible with support from Unitaid, innovating for global health.